1428243-25-7 Usage
Uses
Used in Pharmaceutical Industry:
(3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt is used as a building block for the synthesis of novel pharmaceutical compounds. Its unique structure and chirality make it a promising candidate for the development of new drugs with specific targeting and activity profiles.
Used in Chemical Research:
In the field of chemical research, (3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt can be used as a reagent or intermediate in the synthesis of various organic compounds. Its versatility and the presence of multiple functional groups make it a valuable tool for exploring new reaction pathways and developing innovative synthetic methods.
Used in Materials Science:
(3R,4S)-1-((benzyloxy)carbonyl)-4-ethylpyrrolidine-3-carboxylic acid (R)-1-(naphthalen-1-yl)ethan-1-amine salt may also find applications in materials science, where its unique properties could be exploited to create new materials with specific characteristics. For example, it could be used to develop novel polymers, coatings, or other materials with tailored properties for various industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 1428243-25-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,8,2,4 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1428243-25:
(9*1)+(8*4)+(7*2)+(6*8)+(5*2)+(4*4)+(3*3)+(2*2)+(1*5)=147
147 % 10 = 7
So 1428243-25-7 is a valid CAS Registry Number.
1428243-25-7Relevant academic research and scientific papers
Development of a Scalable Enantioselective Synthesis of JAK Inhibitor Upadacitinib
Bhagavatula, Lakshmi,Christesen, Alan,Dunn, Travis B.,Ickes, Andrew,Kotecki, Brian J.,Marek, James C.,Morrill, Westin H.,Moschetta, Eric,Mulhern, Mathew,Rasmussen, Michael,Reynolds, Troy,Rozema, Michael J.,Yu, Su
, (2021/10/21)
Process development of a six-stage synthesis of upadacitinib, a JAK1 inhibitor, is described. It is highlighted by an enantioselective and diastereoselective hydrogenation of a tetrasubstituted olefin to set the two pyrrolidine stereocenters. Preparation of the main fragments and strategies to link them together, optimization of the imidazole cyclization, and in-depth understanding of the formation of the urea moiety at the final stage are discussed.
ALTERNATE PROCESSES FOR THE PREPARATION OF PYRROLIDINE DERIVATIVES
-
, (2019/02/06)
Aspects of the present application relate to process for the preparation of Pyrrolidine derivatives useful as key intermediates for active ingredients. Specific aspects relate to alternate process for the preparation of Upadacitinib intermediate, 4-ethylpyrrolidine-3-carboxylic acid, its ester or a salt thereof. Processes disclosed here in are cost effective and industrially viable as compared to known processes.
NOVEL TRICYCLIC COMPOUNDS
-
, (2013/03/28)
The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
